Skip Navigation

Eligible for a Bard PowerPort lawsuit?

Jury Returns Defense Verdict in First Bard PowerPort Injury Lawsuit

Jury Returns Defense Verdict in First Bard PowerPort Injury Lawsuit

An Arizona jury has found that C.R. Bard and Becton Dickinson are not liable for failing to warn about potential Bard PowerPort injury risks, but deadlocked on whether the implantable port catheter was defectively designed.

The Bard PowerPort injury lawsuit was the first in a series of scheduled bellwether trials set to go before federal juries in the coming months, involving a claim brought by Robert Cook, who argued that the port catheter was responsible for causing him to suffer a serious infection.

Cook’s case is one of more than 3,000 similar Bard PowerPort lawsuits pending in the federal court system, and was being closely watched to help gauge how juries may respond to certain evidence and testimony likely to be repeated throughout the litigation.

Bard PowerPort Defect Allegations

The PowerPort is a port catheter implant designed to help doctors inject medications and other fluids into a patientโ€™s body without the need for a new needlestick every time. It consists of a small injection port implanted beneath the skin and a polyurethane catheter that delivers the fluids into the patientโ€™s veins. It is often used for chemotherapy and other treatments where numerous repeat injections are anticipated.

However, many individuals have reported in recent years that Bard PowerPort devices are defectively designed after suffering infections, catheter fractures and failures where the implant migrated out of position. 

Plaintiffs allege the manufacturers fraudulently marketed the implants as safe and effective, despite knowing about design problems. They also claim the companies failed to correct the design or warn the medical community about the risk of serious complications, including pulmonary embolism, blood clots, infections and the need for revision surgery to remove failed implants.

Bard PowerPort Lawsuit Lawyers
Bard PowerPort Lawsuit Lawyers

Due to facts and law common throughout the litigation, all federal Bard PowerPort lawsuits have been consolidated for coordinated discovery and pretrial proceedings in the District of Arizona before U.S. District Judge David G. Campbell, who has been working with the parties for months to prepare a series of six bellwether trials to go before juries.

While the outcomes in these early test trials are not binding on other plaintiffs, they are designed to help facilitate potential Bard PowerPort settlement negotiations between the parties and avoid the need for each individual case to go before separate juries nationwide in the coming years.

Bard PowerPort Verdict

The trial over Cookโ€™s claims began on April 21 and concluded Friday. The jury found Bard was not liable for failing to warn or instruct about potential PowerPort risks, and rejected the consumer fraud claim. However, jurors were unable to reach a unanimous verdict on whether the PowerPort was defectively designed or whether the manufacturers engaged in unlawful trade practices.

The split outcome means that future bellwether trials, which may help clarify juriesโ€™ interpretations of the evidence and arguments, could have become even more important.

Jurors reportedly indicated that had they been specifically asked if the Bard PowerPort could have been designed to be safer, they would have said yes. Additionally, company employees testified that they had recommended the portโ€™s design be updated, and that Bard has known for years that its port catheters have a 14% infection rate.

Additional trials are scheduled to begin on July 7, August 18, October 13, December 1, and February 2, 2027. The second trial will involve injuries suffered by Wanda Miller, who died in early February of cancer. To date, Millerโ€™s family has not yet decided whether to move forward with the lawsuit as her heirs. This has raised questions as to whether the case should move forward as scheduled, be rescheduled, swapped with another claim or removed as a bellwether trial entirely.

If the bellwether trials conclude without a settlement or other resolution, Judge Campbell is expected to begin remanding the cases back to their originating federal districts for individual trial dates.

Additionally, more than 300 similar AngioDynamics port catheter lawsuits claim that companyโ€™s series of port catheters, including the Vortex Port, SmartPort and Xcela Port, suffer from a similar problem as the Bard PowerPort. These lawsuits are consolidated in a separate MDL in the Southern District of California before U.S. Judge Jinsook Ohta, who is expected to begin a similar bellwether process in hopes of resolving those claims as well.

Sign up for more legal news that could affect you or your family.

Irvin Jackson
Written By: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.



0 Comments


This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

The second Bard PowerPort bellwether trial is now scheduled to begin in August after the plaintiff in a claim originally planned for trial next month died, and her family stopped pursuing litigation.
A Delaware woman has filed a Dupixent lawsuit, claiming manufacturers promoted the eczema drug as a breakthrough treatment while failing to warn that it may trigger or worsen CTCL, a rare form of non-Hodgkinโ€™s lymphoma.
Federal regulators have expanded an Omnipod recall after reports that internal tubing defects may cause insulin leaks and under-delivery, potentially triggering dangerous blood sugar spikes.